<?xml version="1.0" encoding="ISO-8859-1"?>
<?xml-stylesheet type="text/xsl" href="helma.xsl"?>
<xmlroot xmlns:hop="http://www.helma.org/docs/guide/features/database">
  <hopobject id="2432" name="Page" prototype="Page" created="1363280116832" lastModified="1543237508204">
  <hop:parent idref="0" prototyperef="Root"/>
    <http_browser>Mozilla/4.0 (compatible; MSIE 6.0; Windows NT 5.1; SV1)</http_browser>
    <lang>en-us</lang>
    <uri>bone-update</uri>
    <http_host>127.0.0.1:8080</http_host>
    <time type="date">26.11.2018 13:05:08 UTC</time>
    <pseudoparent idref="0" prototyperef="Root"/>
    <http_remotehost>127.0.0.1</http_remotehost>
    <hopsession>127.0.0.163fsxqxbe1t5</hopsession>
    <user>default</user>
    <pvcount type="float">85.0</pvcount>
    <body>Just over two years &lt;a href=&quot;https://www.brentwood-karting.com/index.php/stmap_6e560.html?bimatoprost.ponstel.levitra.captopril&quot;&gt;nexium 40 mg ne ie yarar yan etkileri&lt;/a&gt;  This tack dovetails with CMS&apos;s draft memo from earlier this week in which it outlined only two situations in which the Amyvid test would be relevant: clinical-trials to fulfill coverage with evidence development requirements and if it&apos;s a close call for determining if a patient&apos;s mental deterioration is due to Alzheimer&apos;s or another condition. Beta amyloid is thought to be a possible cause of the brain disorder.
 </body>
    <http_language>en-US,en;q=0.8</http_language>
    <is_xhtml type="boolean">true</is_xhtml>
    <http_referer>http://beagleboard.org/bone-update/edit</http_referer>
  </hopobject>
</xmlroot>
